Structural optimization method to improve the theranostic performance of peptide receptor-targeted radionuclide therapy for cancers
US12337042B2 · kind B2 · utility
0Cited by
3References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 12, 2024 |
| Grant date | Jun 24, 2025 |
| Priority date | — |
| Expiry date | Jul 12, 2044 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides in certain embodiments a carcinoma-targeting conjugate comprising Formula I: T-L-X
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.